Evidence continues to accumulate suggesting that genetic variation is at least partly responsible for interindividual differences in clinical response to essentially all classes of drugs, including those used to treat patients with epilepsy. Despite the recent emphasis placed upon the concept of pharmacogenetics, it has been difficult to assess accurately the relative importance of gene variation in antiepileptic drug (AED) therapy. To date, the main focus of AED pharmacogenetic research has been older drugs of established clinical value, particularly, phenytoin (PHT) and carbamazepine (CBZ). Other standard agents such as valproic acid (VPA), ethosuximide (ETX), barbiturates and benzodiazepines have not been systematically studied, nor have newer drugs such as gabapentin, lamotrigine (LTG), felbamate, tiagabine, topiramate (TPM), vigabatrin (VGB), oxcarbazepine (OXC), levetiracetam and zonisamide. This limitation in fundamental data prohibits broad application of genetic information in the clinical use of AEDs at the present time.
Impact of pharmacogenetics on antiepileptic drug selection
In determining pharmacological treatment for any new epilepsy patient, a clinician must address two basic questions: 'Which drug?' and 'Which dose?'. Ideally, the answers to these questions lead to an efficacious and well-tolerated AED treatment. Based on clinical trial data, mechanisms of action, and clinical experience, certain AEDs are generally preferred for focal epilepsy (CBZ, OXC, PHT) and other AEDs are preferred for generalized epilepsy (VPA, ETX, LTG, TPM). 1, 2 With rare exceptions, such as VGB as the preferred AED for infantile spasms due to tuberous sclerosis, 3 etiology of epilepsy plays little or no role in AED selection. Similarly, since studies have not yet begun to address genetic determinants of drug efficacy, pharmacogenetics also currently plays no role. There is thus a critical need for prospective studies involving a wider variety of common AEDs in order to begin to develop more rational therapeutic strategies.
Drug efficacy is complicated to study from a pharmacogenetic perspective since it is difficult to distinguish lack of sensitivity of target molecules from inadequate drug access to targets. Drug levels can be measured in serum or plasma, but it is not known how accurately these measurements reflect the levels to which therapeutically critical brain regions are exposed. Thus, genetic variation in both the targets of drug action and molecules regulating pharmacokinetic parameters must be considered. Titration to clinical efficacy circumvents some of the factors that may contribute to interindividual differences in AED responsiveness, but this remains a process of trial and error. No studies have been published that address the question of whether a specific AED will be efficacious based on genotype.
As AED tolerability is also critical, there is hope that pharmacogenetic advances will be able to identify patients likely to experience idiosyncratic side effects. Thus, certain AEDs could be avoided in susceptible patients. To date, there is one report of a very strong association between HLA allele B*1502, CBZ and Stevens Johnson Syndrome (SJS) in Han Chinese patients. 4 If replicated, this finding could become a model of the potential for pharmacogenetics to influence AED choice and benefit patients. However, it should be noted that confirming the finding in a more ethnically diverse population may be challenging since HLA B*1502 allele frequency in Caucasians for example is 4-8 times less than in Han Chinese.
The timing and severity of more chronic AED side effects, such as weight gain, weight loss, decreased bone density, cognitive dysfunction, and mood alteration, may also be influenced by genotype. Identification of patients likely to develop side effects could impact specific AED choice. Better understanding of the mechanisms involved in the development of these adverse effects could lead to strategies to circumvent their occurrence if certain AEDs must be prescribed for particular patients.
Impact of pharmacogenetics on antiepileptic drug dose
Antiepileptic drug dosing involves four steps -starting dose, titration rate, initial maintenance dose, and maximally tolerated dose. In parallel to the difficulties inherent in basing AED choice on anticipated efficacy, dosing decisions are also based upon trial and error. Pharmacogenetics offers the potential to influence dosing decisions based on patient genotype. For PHT and CBZ, there are several genetic polymorphisms that have putative or confirmed clinical implications for dosing regimen. First, the initial association between polymorphism in genes for the PHT metabolizing enzyme CYP2C9 and pharmacokinetic parameters of PHT treatment 5, 6 has been confirmed. 7 More recent studies provide additional confirmation of influence of CYP2C9 genotype on PHT treatment by showing that patients harboring the *3 allele exhibit a modest (10-15%) but significant reduction in maximum tolerated dose of PHT. 8 It is estimated that only a small portion (less than 10%) of the variance in the maximum tolerated dose of PHT was explained by polymorphism at the CYP2C9 locus. 8 It is also noteworthy that patients harboring CYP2C9 variants with very low enzymatic activity (e.g. *3 exhibits less than 10% of wild-type activty) may still tolerate standard doses of PHT. These findings reflect the highly multifactorial nature of PHT detoxification and suggest that other relevant pharmacogenetic associations remain to be discovered. In another study, estimated daily doses required to keep PHT in the usual reference boundaries of 10-20 mg/l ranged from 2-3 to 5.5-7 mg/kg/day based on genotyping of polymorphisms in CYP2C9 and CYP2C19. 7 The other genetic factor putatively associated with AED treatment is SCN1A. 8 It represents the first strong association between a clinically relevant AED end point and a gene that encodes a therapeutic target for the AED and if confirmed could have a significant impact on treatment paradigms. Specifically, maximal tolerated doses of both PHT and CBZ were found to be related to SCN1A genotype at the IVS5-91 G4A locus with the minor allele (G) associated with 10-15% reductions in maximal tolerated dose of PHT and 15-20% reductions in maximal tolerated dose of CBZ. 8 Maximum PHT doses varied from 326 to 373 mg per day and maximum CBZ doses varied from 1083 to 1313 mg per day depending on SCN1A genotype. Evidence also suggests that combining genotype at the SCN1A locus with genotype at CYP2C9 locus helps further to predict the maximally tolerated dose of PHT. 8 Although the influence of CYP2C9 and SCN1A genotype did not lead to striking influences in maximum PHT and CBZ doses, results suggest the potential for faster titration schedules in patients with greater ability to metabolize or respond to the drug. Thus, adjusting titration schedule based on genotype could lead to more rapid achievement of AED efficacy with acceptable tolerability, even if the maximum dose is relatively standard.
Predicting refractory epilepsy
There is hope that better understanding of AED access to the critical site of action will partially explain why some patients are refractory to multiple AEDs. Emphasis has been placed on analyzing polymorphisms in genes encoding drug efflux transporters, which transport AEDs and other drugs out of cells. The 3435C4T polymorphism in the ABCB1 drug transporter gene, or a haplotype that includes this variation, has been correlated with lack of efficacy to multiple AEDs. [9] [10] [11] Although these findings have not been confirmed by all investigators, 12, 13 such work has the potential to identify patients who could be early candidates for non-AED treatments such as brain stimulation or surgery. With improved understanding of AED transport mechanisms, it may also be possible to develop methods of circumventing drug efflux transporters, and improve access of AEDs to critical sites of action in the brain.
Summary
Although it is not yet possible to make general recommendations for the incorporation of genetic data into decision-making process for AED therapy, recent studies are beginning to provide a foundation for the future establishment of treatment guidelines. Data from these studies can be used to refine candidate gene hypotheses for possible confirmation in independent populations treated with traditional AEDs and can also help to inform study design for the investigation of newer drugs as well. Documentation of the clinical relevance of variation in genes encoding drug target (SCN1A), drug transport (ABCB1) and drug metabolizing (CYP2C9, CYP2C19) proteins strengthens the rationale for future studies and provides clues for better integrating genetic information into epilepsy pharmacotherapy. To date, there are two clinical end points that have been studied in connection with AED pharmacogenetics, maximum tolerated dose and serum drug level. Although these measures help to guide treatment in a general way, they are not necessarily predictive of clinical success. In order to begin to address the key questions pertaining to genetics and AED therapy, future studies must combine pharmacokinetic data with standardized clinical outcome measures of efficacy and tolerability. This will better help to define the relationship between gene variation and the clinical use of AEDs and will provide the most rational treatment options for patients with epilepsy.
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